RxDoctor Payments Data

Kirk Levy, MD

Neurology · Englewood, NJNPI 1023077393

Payments from drug & device makers

$31,056in general payments, 2019–2025

Across 1,387 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$9K
  • Teva Pharmaceuticals USA, Inc.$4K
  • AbbVie$2K
  • Lundbeck LLC$1K
  • Novartis$875
  • EMD Serono, Inc.$857
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$5,32517%
  • Speaking & faculty fees$150%
  • Travel & lodging$7282%
  • Food & beverage$24,73380%
  • Education$2541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.130$8,848
Teva Pharmaceuticals USA, Inc.262$3,736
AbbVie(2 entities)156$1,761
Lundbeck LLC58$1,160
Novartis63$875
EMD Serono, Inc.40$857
Lilly USA, LLC30$828
Avadel CNS Pharmaceuticals, LLC32$810
Harmony Biosciences LLC34$777
Neurocrine Biosciences, Inc.52$771
Jazz Pharmaceuticals Inc.28$756
Amgen17$677
Acadia Pharmaceuticals Inc30$660
Eisai Inc.24$584
Pfizer44$567
Bristol Myers Squibb35$519
CSL Behring22$478
Biogen21$461
Inspire Medical Systems, Inc.4$444
Axsome Therapeutics, Inc.13$438
Argenx US, Inc.38$426
AstraZeneca(2 entities)21$358
UCB, Inc.19$348
TG Therapeutics, Inc.9$253
Otsuka America Pharmaceutical, Inc.14$233
Biohaven Pharmaceuticals, Inc.5$212
Kyowa Kirin, Inc.13$203
E.r. Squibb & Sons, L.L.C.5$187
Greenwich Biosciences, Inc.4$186
Ceribell, Inc.1$161
Johnson & Johnson10$148
Acorda Therapeutics, Inc9$140
Neurelis, Inc.9$140
Azurity Pharmaceuticals, Inc.8$137
Aucta Pharmaceuticals, Inc.11$136
Alnylam Pharmaceuticals Inc.9$135
Upsher-smith Laboratories LLC9$130
Adamas Pharmaceuticals, Inc.8$105
MDD US Operations, LLC7$104
W. L. Gore & Associates, Inc.7$98
Arbor Pharmaceuticals, Inc.7$98
Genentech USA, Inc.6$92
Ipsen Biopharmaceuticals, Inc5$88
Merz Pharmaceuticals, LLC5$85
Sanofi5$75
Biohaven Pharmaceutical Holding Company Ltd.5$74
GE HealthCare4$67
Aquestive Therapeutics, Inc.3$55
Scilex Pharmaceuticals Inc.3$48
Catalyst Pharmaceuticals, Inc.2$44
Supernus Pharmaceuticals, Inc.3$44
Octapharma USA, Inc.3$41
Abbott2$37
Corium, LLC2$33
Avion Pharmaceuticals2$31
Almatica Pharma LLC2$30
Amneal Pharmaceuticals LLC2$30
Vertical Pharmaceuticals, LLC2$29
Neuronetics, Inc.1$26
Assertio Therapeutics, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,056 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$310,203
Medicare patients
1,046
Services billed
2,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate26$144,992
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$109,047
Avonex Pen (4 Pack)Interferon Beta-1a11$87,615
BriviactBrivaracetam40$74,716
XcopriCenobamate45$55,914
VimpatLacosamide18$41,508
RytaryCarbidopa/Levodopa50$41,375
Emgality PenGalcanezumab-Gnlm54$40,828
LamictalLamotrigine31$38,449
Nurtec OdtRimegepant Sulfate39$37,008
Aimovig AutoinjectorErenumab-Aooe44$34,378
QuliptaAtogepant24$28,270
Ajovy AutoinjectorFremanezumab-Vfrm25$27,117
UbrelvyUbrogepant21$21,937
Lamotrigine ErLamotrigine37$21,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$660$144,99226 claims
UCB, Inc.Briviact, Vimpat$348$116,22558 claims
SK Life Science, Inc.Xcopri$8,848$55,91445 claims
AbbVieQulipta, Ubrelvy$1,761$50,20745 claims
Amneal Pharmaceuticals LLCRytary$30$41,37550 claims
PfizerNurtec Odt, Dilantin$567$41,01250 claims
Arbor Pharmaceuticals, Inc.Horizant$98$19,05819 claims
Upsher-smith Laboratories LLCTopiramate$130$2,237104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →